Ortonne J P, Humbert P, Nicolas J F, Tsankov N, Tonev S D, Janin A, Czernielewski J, Lahfa M, Dubertret L
Hôpital de l'Archet 2, Nice, France.
Br J Dermatol. 2003 Feb;148(2):326-33. doi: 10.1046/j.1365-2133.2003.05228.x.
Psoriasis involving sensitive skin areas remains difficult to treat because of the side-effects of topical corticosteroids and the irritancy potential of vitamin D3 derivatives. Several clinical trials have demonstrated that calcitriol, the naturally occurring and hormonally active form of vitamin D3, is effective and safe at the dose of 3 microg g(-1) for the treatment of psoriasis affecting the trunk and limbs.
We compared the safety and efficacy of calcitriol 3 microg g(-1) ointment and calcipotriol 50 microg g(-1) ointment in a multicentre, randomized, investigator-blinded, left-right comparison in mild to moderate chronic plaque psoriasis affecting sensitive areas, defined as being the face, hairline, retroauricular and flexural areas. One pair of symmetrical and bilateral target lesions was selected from each area and assessed for perilesional erythema, oedema, and stinging/burning. Global assessment of local tolerability and global improvement were rated by the investigator, and the subjects were asked to evaluate the tolerability and efficacy of each product and to express their global preference.
In the 75 subjects, calcitriol and calcipotriol both led to clearing of at least one target lesion in 21 (28%) of the subjects each. Perilesional erythema (P < 0.001), perilesional oedema (P < 0.02) and stinging/burning (P < 0.001) were all significantly less severe with calcitriol than with calcipotriol. The subjects' evaluation of local tolerability was significantly (P < 0.0001) in favour of calcitriol. Ten treatment-related dermatological events occurred in eight subjects, including one subject who experienced skin discomfort on both sides. All other events occurred only on the calcipotriol-treated side (irritant dermatitis, six subjects; contact dermatitis, one subject). Global assessment of improvement from baseline by the investigators was significantly greater for the calcitriol-treated lesions (P < 0.02). The subjects' global preference was significantly in favour of calcitriol (P < 0.02).
In the present study, calcitriol ointment was found to be better tolerated and would appear to be more effective than calcipotriol ointment in the treatment of psoriasis in sensitive areas.
由于外用糖皮质激素的副作用以及维生素D3衍生物的潜在刺激性,累及敏感皮肤区域的银屑病仍然难以治疗。多项临床试验表明,骨化三醇(维生素D3的天然存在且具有激素活性的形式)以3μg g(-1)的剂量治疗累及躯干和四肢的银屑病有效且安全。
我们在一项多中心、随机、研究者盲法、左右对照试验中,比较了3μg g(-1)骨化三醇软膏和50μg g(-1)卡泊三醇软膏治疗累及敏感区域(定义为面部、发际线、耳后和屈侧区域)的轻至中度慢性斑块状银屑病的安全性和疗效。从每个区域选择一对对称的双侧靶皮损,评估皮损周围红斑、水肿和刺痛/灼痛情况。研究者对局部耐受性和整体改善情况进行整体评估,受试者被要求评估每种产品的耐受性和疗效,并表达他们的整体偏好。
在75名受试者中,骨化三醇和卡泊三醇均使21名(28%)受试者的至少一个靶皮损消退。骨化三醇治疗组的皮损周围红斑(P < 0.001)、皮损周围水肿(P < 0.02)和刺痛/灼痛(P < 0.001)均明显轻于卡泊三醇治疗组。受试者对局部耐受性的评估明显(P < 0.0001)有利于骨化三醇。8名受试者发生了10起与治疗相关的皮肤事件,其中1名受试者双侧均出现皮肤不适。所有其他事件仅发生在卡泊三醇治疗侧(刺激性皮炎,6名受试者;接触性皮炎,1名受试者)。研究者对骨化三醇治疗皮损从基线开始的改善情况的整体评估明显更好(P < 0.02)。受试者的整体偏好明显有利于骨化三醇(P < 0.02)。
在本研究中,发现骨化三醇软膏耐受性更好,在治疗敏感区域的银屑病方面似乎比卡泊三醇软膏更有效。